This study covers the latent demand outlook for biosimilars and follow-on biologics drugs across the granular markets of Iceland. A granular market, often referred to as a "populated place", includes core cities, suburbs, officially designated neighborhoods, villages, towns and/or hamlets. Many larger cities, therefore, have been divided into more granular entities, or are disaggregated to a very local level. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across markets in Iceland. For each granular market in question, the percent share the market is of Iceland as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a market vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each market, latent demand estimates are created for biosimilars and follow-on biologics drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

In this report we define the sales of biosimilars and follow-on biologics drugs as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Allergan, Allozyne, Alteogen, Alvogen, Amarey Novamedical, AMEGA Biotech, Amgen, Apotex, Astellas Pharma, AstraZeneca, Avesthagen, Baxter, Bayer, Beijing Four Rings, BIOCAD, Bioceuticals, Biocon, Biogen, Biolab, Bionovis, Biopartners, Biosidus, Bioton, BioXpress Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Cambridge Antibody Technology, CCL Pharmaceuticals, CCM Duopharma, Celltrion, Centocor Ortho Biotech, Chong Kun Dang, Chugai, CinnaGen., Coherus BioSciences, Compass Biotechnologies, Cristália, CT Arzneimittel, Cyplasin, Daiichi Sankyo, Dong-A Pharmaceutical, Dr. Reddy’s Laboratories, Egis Pharmaceuticals, Eisai, Eli Lilly, Elpen Pharmaceutical, Emcure Pharmaceuticals, EMS, Epirus, Eurofarma, Express Scripts, FibroGen, Finox Biotech, Fuji Pharma, Gan & Lee, Genetech, Genexine, Gennova, GenSci, Genzyme, Geropharm, Gilead Sciences, GlaxoSmithKline, Hangzhou Jiuyuan Gene Engineering Company, Hanmi Pharmaceutical, Hanwha Chemical, Haselmeier, Health Canada, Helius Biotech, Hexal, Hindustan Antibiotic, Hospira, Hualida Biotech, Hypermarcas, IGES Institute, Intas Biopharmaceuticals, inVentiv Health, JCR Pharmaceuticals, Johnson & Johnson, Kabi, Kemwell Biopharma, Kissea, Koçak Farma, Kwizda Pharma, Kyowa Hakko Kirin, Landsteiner Scientific, LG Life Sciences, Libbs, LKM SA, Lonza Group, Mabion, Marvel Life Sciences, MEDICE Arzneimittel Pütter, Merck (MSD), Minapharm, Mitsubishi Tanabe, Mochida Pharmaceutical, Momenta Pharmaceuticals, Mycenax Biotech, Mylan, Nichi-Iko, Nippion Kayaku, Novartis, Novo Nordisk, Nuron Biotech, Oncobiologics, Ortho Pharmaceutical, Orygen, PanGen Biotech, Pfenex, Pfizer, Pharmapark, Pharmstandard, PRA International, Pro Generika, Qilu Pharmaceutical, Quintiles, Ranbaxy Laboratories, RAND Corporation, Ratiopharm, Regeneron Pharmaceuticals, Reliance GeneMedix, Rentschler Biotechnologie, Roche, Samsung Bioepis, Sandoz, Sanofi, SciGen, Shandong Kexing Pharma, Shanghai Celgen Biopharmaceutical, Shantha Biotechnics, Shinogi, Sicor Biotech, Sothema Laboratories, Spectrum Pharmaceuticals, Stada Arzneimittel, Stragen Pharma, Strides Arcolab, Syngene International, Synthon Biopharmaceuticals, Takeda, Teva, Tianjin Hualida Biotechnology, Tonghua Dongbao, TSH Biopharm, União Química, USV Biologics, Virchow Biotech, Wanbang Biopharmaceuticals, Wockhardt, Xiamen Amoytop Biotech, Zenotech, Zhejian Huahai Pharmaceutical, Zuventus, and Zydus Biovation. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2024).

This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all granular markets in Iceland). This study gives, however, Professor Parker's estimates for the latent demand, or potential industry earnings (P.I.E.), for biosimilars and follow-on biologics drugs in Iceland. It also shows how the P.I.E. is divided and concentrated across the granular markets of Iceland (e.g., cities, towns, villages, etc.). For each granular market, he also shows his estimates of how the P.I.E. grows over time. In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on strategic planning at graduate schools of business.

• 1INTRODUCTION
• 1.1OVERVIEW
• 1.2WHAT IS LATENT DEMAND AND THE P.I.E.?
• 1.3THE METHODOLOGY
• 1.3.1STEP 1. PRODUCT DEFINITION AND DATA COLLECTION
• 1.3.2STEP 2. FILTERING AND SMOOTHING
• 1.3.3STEP 3. FILLING IN MISSING VALUES
• 1.3.4STEP 4. VARYING PARAMETER, NON-LINEAR ESTIMATION
• 1.3.5STEP 5. FIXED-PARAMETER LINEAR ESTIMATION
• 1.3.6STEP 6. AGGREGATION AND BENCHMARKING
• 1.4FREQUENTLY ASKED QUESTIONS (FAQ)
• 1.4.1CATEGORY DEFINITION
• 1.4.2UNITS
• 1.4.3METHODOLOGY
• 2GRANULAR FINDINGS
• 2.1LATENT DEMAND IN ICELAND - GRANULAR MARKETS SORTED BY RANK
• 2.2LATENT DEMAND IN ICELAND - GRANULAR MARKETS SORTED ALPHABETICALLY
• 2.3LATENT DEMAND BY YEAR IN ICELAND
• 3DISCLAIMERS, WARRANTIES, AND USER AGREEMENT PROVISIONS
• 3.1DISCLAIMERS & SAFE HARBOR
• 3.2ICON GROUP INTERNATIONAL, INC. USER AGREEMENT PROVISIONS